Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Humulin M30 (also known as Humulin M3 or Humulin 30/70) is a biphasic isophane human insulin suspension. It is a premixed formulation containing 30% soluble insulin (rapid-acting regular human insulin) and 70% isophane insulin (intermediate-acting NPH insulin). This combination provides dual-phase glucose control, where the soluble component rapidly manages postprandial blood glucose spikes and the isophane component provides sustained basal insulin coverage. Humulin M30 is administered subcutaneously and is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve glycemic control.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on biphasic insulin human.